指南与共识皮肤感染

印度毛癣菌共识建议:改良德尔菲研究

Consensus recommendations for Trichophyton indotineae: A modified Delphi study.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2026-09-25

该改良德尔菲研究针对全球扩散且常耐特比萘芬的印度毛癣菌(T. indotineae)制定诊疗共识。34名专家受邀,20人完成前两轮、19人完成后两轮,42项中34项(80.95%)达成共识。共识建议对广泛或特比萘芬难治性皮肤癣菌病及有流行区旅行史者警惕该菌,诊断推荐KOH镜检、真菌培养及PCR/ITS测序确认,耐药评估优选SQLE测序和药敏试验,治疗推荐口服伊曲康唑100-200 mg/日6-8周,卢立康唑1%乳膏为优选辅助外用,伊曲康唑失败后可考虑泊沙康唑300 mg/日4-12周作为挽救治疗。

要点

  • 广泛或特比萘芬难治性皮肤癣菌病、有流行区旅行史者应怀疑印度毛癣菌感染。
  • 诊断推荐KOH镜检和真菌培养,PCR种级鉴定或ITS测序确认印度毛癣菌。
  • 治疗推荐口服伊曲康唑100-200 mg/日6-8周,卢立康唑1%乳膏为优选辅助外用。

核心结论

  • 共识为印度毛癣菌感染的诊断和治疗提供实用临时建议,仍需随机对照试验验证疗效和优化方案。

研究设计与样本

  • 四轮改良德尔菲研究, steering group制定基于文献的42项诊断与管理问卷,共识预设为≥70%同意。
  • 34名专家受邀,20人完成第1和第2轮,19人完成第3和第4轮。

主要发现

  • 42项中34项(80.95%)达成共识。
  • panel建议对广泛或特比萘芬难治性皮肤癣菌病患者、尤其有流行区旅行或居住史者怀疑印度毛癣菌感染。

关键数值与推荐

  • 诊断疑似皮肤癣菌感染推荐KOH直接镜检和真菌培养,确认印度毛癣菌推荐PCR种级鉴别或ITS测序。
  • 耐药评估优选SQLE测序和抗真菌药敏试验(尤其治疗失败后)。
  • 治疗印度毛癣菌所致浅部真菌感染推荐口服伊曲康唑100-200 mg/日6-8周(或按临床需要延长),卢立康唑1%乳膏为优选辅助外用。
  • 伊曲康唑失败后可考虑口服泊沙康唑300 mg/日4-12周作为挽救治疗,需注意抗真菌药物管理。

临床怎么用

  • 对广泛或特比萘芬难治性皮肤癣菌病及有流行区旅行史者应怀疑印度毛癣菌并送检确认。
  • 确诊后按共识选用伊曲康唑口服联合卢立康唑外用,伊曲康唑失败可考虑泊沙康唑挽救并关注药物管理。

局限性

  • 共识为临时建议,需随机对照试验验证结局和优化方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trichophyton indotineae (T. mentagrophytes genotype VIII) is spreading globally and is often terbinafine resistant. Guidance for diagnosis and treatment remains inconsistent. METHODS: We performed a four-round modified Delphi study. A steering group developed a literature-informed, 42-item questionnaire on diagnosis and management. Consensus was predefined as ≥70% agreement. RESULTS: Thirty-four experts were invited; 20 completed rounds 1 and 2 and 19 completed rounds 3 and 4. Consensus was achieved for 34/42 items (80.95%). The panel advised suspecting T. indotineae infection in patients with extensive or terbinafine-recalcitrant dermatophytosis, particularly those with a history of travel to or residence in endemic regions. For diagnosis, the panel recommended KOH direct microscopy and fungal culture for suspected dermatophyte infection, and PCR (polymerase chain reaction) with species-level discrimination or ITS sequencing for confirmation of T. indotineae. For resistance assessment, SQLE sequencing and antifungal susceptibility testing were preferred where available, particularly after treatment failure. For treating superficial fungal infections caused by T. indotineae, experts recommended oral itraconazole therapy (100-200 mg/day for 6-8 weeks, or longer as clinically indicated), with luliconazole 1% cream as the preferred adjunctive topical option. Oral posaconazole (300 mg/day for 4-12 weeks) can be considered as the salvage therapy following itraconazole failure, keeping in mind antifungal stewardship. CONCLUSIONS: These consensus statements provide practical interim recommendations. Randomized controlled trials are needed to validate outcomes and optimize regimens.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Gupta AK, Talukder M, Saunte DML, et al. Consensus recommendations for Trichophyton indotineae: A modified Delphi study. J Eur Acad Dermatol Venereol. 2026. PMID: 42786909. doi:10.1111/jdv.70731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。